Table 2. Features.
All features (89) | Feature set A (42) | Feature set B (20) | Feature set C (23) |
---|---|---|---|
Age | • | • | • |
Sex | • | ||
Height | |||
Weight | |||
Body mass index | • | ||
ASA classification | |||
Comorbidities | |||
Cardiovascular disease | |||
Hypertension | • | ||
Atrial fibrillation | |||
Coronary artery disease | • | ||
Angina pectoris | • | ||
Congestive heart failure | • | ||
Respiratory disease | |||
Asthma | • | ||
Chronic obstructive pulmonary disease | • | ||
Gastrointestinal disease | |||
Hepatitis | • | ||
Liver cirrhosis | • | ||
Viral carrier | • | ||
Hepatitis B viral infection | |||
Renal disease | |||
Chronic kidney injury | • | ||
End-stage renal disease | • | ||
Endocrine disease | |||
Diabetes mellitus | • | ||
HbA1c | |||
Thyroid disease | • | ||
Neurologic disease | |||
Cerebrovascular disease | • | ||
Cerebral aneurysm | • | ||
Baseline blood pressure | |||
Systolic | • | ||
Mean | • | ||
Diastolic | • | • | |
Noninvasive blood pressure† | |||
Systolic min | • | • | |
Systolic max | • | ||
Systolic mean | • | • | |
Systolic sd | • | • | |
Mean min | • | • | |
Mean max | • | ||
Mean mean | • | • | |
Mean sd | • | • | |
Diastolic min | • | ||
Diastolic max | |||
Diastolic mean | • | • | |
Diastolic sd | |||
Heart rate† | |||
min | • | ||
max | • | • | |
mean | • | ||
Anesthetic drug† | |||
Volume | |||
Propofol min | |||
Propofol max | • | • | • |
Propofol mean | • | • | |
Remifentanil min | • | ||
Remifentanil max | • | • | |
Remifentanil mean | • | • | • |
Plasma concentration | |||
Propofol min | |||
Propofol max | • | • | • |
Propofol mean | |||
Remifentanil min | |||
Remifentanil max | |||
Remifentanil mean | |||
Effect-site concentration | |||
Propofol min | |||
Propofol max | |||
Propofol mean | |||
Remifentanil min | • | ||
Remifentanil max | |||
Remifentanil mean | • | ||
Target concentration | |||
Propofol min | • | ||
Propofol max | |||
Propofol mean | |||
Remifentanil min | • | ||
Remifentanil max | |||
Remifentanil mean | • | • | |
Vasoactive drug administration† | |||
Ephedrine | |||
Ephedrine volume | • | ||
Phenylephrine | • | ||
Phenylephrine volume | |||
Esmolol | • | ||
Esmolol volume | |||
Labetalol | • | ||
Labetalol volume | |||
Mechanical ventilation data† | |||
Tidal volume min | • | ||
Tidal volume max | • | • | |
Tidal volume mean | • | • | |
Minute ventilation min | |||
Minute ventilation max | • | ||
Minute ventilation mean | |||
Respiratory rate min | • | ||
Respiratory rate max | • | ||
Respiratory rate mean | • | ||
Max positive airway pressure min | • | ||
Max positive airway pressure max | • | ||
Max positive airway pressure mean | • | ||
Hypotension† | |||
Frequency | • | ||
Duration | • | ||
Average duration | • | • |
Initially, 100 features were selected; however, no patients had 11 comorbidities: myocardial infarction, valve disease, hepatitis C viral infection, fatty liver, alcoholic liver disease, autoimmune liver disease, acute kidney injury, myasthenia gravis, morbid obesity, epilepsy, or dementia. Thus, these features were excluded.
†Features observed between anesthesia induction and tracheal intubation.